To review the use of testosterone for the prevention of bone loss in men with HIV infection.
DATA SOURCES:
A MEDLINE search (1966–May 2002) on the use of testosterone in osteoporosis/HIV infection was performed. A reference bibliography search was also completed.
DATA SYNTHESIS:
Osteopenia/osteoporosis is reported in HIV-infected men due to a myriad of factors. Sex hormone deficiency is a frequent endocrine abnormality in this population.
CONCLUSIONS:
In HIV-negative men, testosterone may be beneficial for preventing bone loss and hastening the resolution of fractures. Testosterone's role in preventing bone loss in HIV-infected men remains to be defined.
KuhneCAHeufelderAEHofbauerLC. Bone and mineral metabolism in human immunodeficiency virus infection. J Bone Mineral Res2001; 6: 2–9.
4.
KatznelsonLFinkelsteinJSSchoenfeldDARosenthalDIAndersonEJKlibanskiA.Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab1996; 81: 4358–65.
5.
BehreHMKlieschSLeifkeELinkTMNieschlagE.Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab1997; 82: 2386–90.
6.
AndersonFHFrancisRMPeastonRTWastellHJ. Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption. J Bone Min Res1997; 12: 472–8.
7.
FairfieldWPFinkelsteinJSKlibanskiAGrinspoonSK. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. J Clin Endocrinol Metab2001; 86: 2020–6.
8.
RingeJDOrwollEDaifotisALombardiA.Treatment of male osteoporosis: recent advances with alendronate. Osteoporosis Int2002; 13: 195–9.
